

Oncimmune Appoints Meinhard Schmidt as Chairman

Nottingham, UK - 14th September 2015: Oncimmune, a leader in early cancer detection, today announced the appointment of Meinhard Schmidt as Non-Executive Chairman.

Meinhard has more than 25 years international experience as an entrepreneur and senior executive in the diagnostics and medical devices industries. Between 1998 and 2008 he was at Roche Diagnostics where he held various global senior leadership roles and was global Senior VP at Lab Diagnostics, which achieved the leading global position in the laboratory industry.

Meinhard has strong board level experience and has worked across M&A, global operations, sales and marketing, program and innovation management and has held executive management positions in Germany, The Netherlands, USA, Canada, Sweden, UK and Switzerland. He currently serves as Board Director at Sphere Medical PLC, valuationLAB AG, CeQur AG and as Chairman at Promimic AB.

Meinhard Schmidt said: “The early detection of cancer can transform outcomes for patients. Oncimmune’s *EarlyCDT*[®] technology has an excellent scientific pedigree, has been extensively validated and *EarlyCDT*[®]-Lung is already on the market in the US, UK and other territories. With the prospect of building on the technology platform to expand into additional cancer types and reach new markets, Oncimmune is poised for growth and I’m very pleased to become Chairman at this exciting time in the Company’s development.”

Geoffrey Hamilton-Fairley, CEO of Oncimmune Limited said: “It is a great pleasure to welcome Meinhard as Chairman of Oncimmune. His industry experience is exceptional and I very much look forward to working with him as we accelerate the next stage in the Company’s development, namely the further commercialisation of *EarlyCDT*[®]-Lung on a global basis and the launch of our new *EarlyCDT*[®] cancer tests. Meinhard’s commercial expertise will enable us to realise the potential of our pioneering autoantibody approach to cancer detection.”

EarlyCDT[®]-Lung is being used in the world's largest randomised trial for the early detection of lung cancer using biomarkers ever conducted; the National Health Service (NHS) Scotland ECLS study of more than 10,000 high-risk smokers. Early results showing a cancer detection rate of 81%, better than the stated test performance, were [recently presented at the 16th World Conference on Lung Cancer](#).

About Oncimmune

Oncimmune is an industry leader in early cancer detection. The company has pioneered the development of autoantibody assay technologies that have the



potential to allow earlier cancer detection than other methods and be applied to a very wide range of solid tumour types. The Company's proprietary *EarlyCDT*[®] technology platform was launched in 2009 and *EarlyCDT*[®]-Lung is available through physicians in the US and also privately in the UK and other regions. *EarlyCDT*[®] tests for liver and ovarian cancer are in final validation.

Oncimmune is headquartered in Nottingham, United Kingdom with testing facilities in the US.

For more information: www.oncimmune.com

Media Contacts:

UK/Europe:

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

Consilium Strategic Communications

oncimmune@consilium-comms.com

+44 (0) 20 3709 5813